Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 4/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 8/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | PPARA | Q07869 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4888601 | 0.96 | VDR (0.92) | VDRRAB9AKMT2AS1PR1NPC1 | |
| SCHEMBL2854911 | 0.94 | VDR (0.88) | VDRMAOBALOX5MAOA | |
| SCHEMBL2641441 | 0.91 | VDR (0.84) | VDRRAB9AKMT2AS1PR1NPC1 | |
| SCHEMBL3832679 | 0.91 | VDR (0.84) | VDRRAB9AKMT2AS1PR1NPC1 | |
| SCHEMBL6563016 | 0.89 | VDR (0.80) | VDRS1PR1MAOBALOX5S1PR5 | |
| SCHEMBL4884277 | 0.88 | VDR (0.79) | VDR | |
| SCHEMBL4893153 | 0.87 | VDR (0.83) | VDRALOX5 | |
| SCHEMBL4881104 | 0.87 | VDR (0.77) | VDRRAB9AKMT2AS1PR1NPC1 | |
| SCHEMBL6564164 | 0.87 | VDR (0.77) | VDRS1PR1MAOBALOX5PPARD | |
| SCHEMBL6576788 | 0.87 | VDR (0.76) | VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243297-A1 | PETROLEUM JELLY-FREE UNGUENT COMPOSITIONS COMPRISING VITAMIN D COMPOUNDS AND OPTIONALLY STEROIDAL ANTI-INFLAMMATORY AGENTS | GALDERMA S.A. (CH) | 2014-08-28 | — | — | US | claimed |
| US-8741878-B2 | Petroleum jelly-free unguent compositions comprising vitamin D compounds and optionally steroidal anti-inflammatory agents | GALDERMA S.A. (CH) | 2014-06-03 | — | — | US | claimed |
| US-8741879-B2 | Petroleum jelly-free unguent compositions comprising vitamin D compounds and optionally steroidal anti-inflammatory agents | GALDERMA S.A. (CH) | 2014-06-03 | — | — | US | claimed |
| US-20130012484-A1 | PETROLEUM JELLY-FREE UNGUENT COMPOSITIONS COMPRISING VITAMIN D COMPOUNDS AND OPTIONALLY STEROIDAL ANTI-INFLAMMATORY AGENTS | GALDERMA S.A. (CH) | 2013-01-10 | — | — | US | claimed |
| EP-2419082-A2 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A WATER-SENSITIVE ACTIVE PRINCIPLE | Galderma S.A. (CH) | 2012-02-22 | — | — | EP | claimed |
| US-20120004200-A1 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A WATER-SENSITIVE ACTIVE PRINCIPLE | GALDERMA S.A. (CH) | 2012-01-05 | — | — | US | claimed |
| EP-1814847-B1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | GALDERMA RES & DEV (FR) | 2011-01-12 | — | — | EP | claimed |
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-11-11 | — | — | US | claimed |
| WO-2010072958-A2 | TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A WATER-SENSITIVE ACTIVE PRINCIPLE | GALDERMA S.A. (CH) | 2010-07-01 | — | — | WO | claimed |
| US-7638657-B2 | Preparation of 3-[5′-(3,4-bis(hydroxymethyl)benzyloxy)-2′-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-12-29 | — | — | US | claimed |
| EP-1885374-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN OLEAGINOUS OINTMENT AND VITAMIN D OR THE DERIVATIVES THEREOF IN SOLUBILISED FORM | Galderma Research & Development (FR) | 2008-02-13 | — | — | EP | claimed |
| US-20070282136-A1 | Preparation of 3-[5'-(3,4-bis(hydroxymethyl)benzyloxy)-2'-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-12-06 | — | — | US | claimed |
| EP-1814847-A1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | Galderma Research & Development (FR) | 2007-08-08 | — | — | EP | claimed |
| WO-2006134272-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ORGANOPOLYSILOXANE ELASTOMER AND A SOLUBILIZED ACTIVE PRINCIPLE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-12-21 | — | — | WO | claimed |
| WO-2006123031-A2 | PHARMACEUTICAL COMPOSITION COMPRISING AN OLEAGINOUS OINTMENT AND VITAMIN D OR THE DERIVATIVES THEREOF IN SOLUBILISED FORM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-11-23 | — | — | WO | claimed |
| WO-2006053985-A1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-05-26 | — | — | WO | claimed |
| US-20060029623-A1 | Invert emulsions comprising at least one active agent sensitive to water and cosmetic/dermatological applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2006-02-09 | — | — | US | claimed |
| EP-1592452-A2 | INVERT EMULSION TYPE COMPOSITION CONTAINING AT LEAST ONE ACTIVE AGENT SENSITIVE TO THE PRESENCE OF WATER, AND ITS USES IN COSMETICS AND IN DERMATOLOGY | Galderma Research & Development, S.N.C. (FR) | 2005-11-09 | — | — | EP | claimed |
| US-6924400-B2 | Triaromatic vitamin D analogues | GALDERMA RESEARCH & DEVELOPMENT, SNC (FR) | 2005-08-02 | — | — | US | claimed |
| WO-2004069134-A2 | INVERT EMULSION TYPE COMPOSITION CONTAINING AT LEAST ONE ACTIVE AGENT SENSITIVE TO THE PRESENCE OF WATER, AND ITS USES IN COSMETICS AND IN DERMATOLOGY | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-08-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286285-A1 | Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state | CYP24A1, VDR, CYP2R1 | VDR 2/4885RAB9A 4442/4885KMT2A 4297/4885 |
| US-20070282136-A1 | Preparation of 3-[5'-(3,4-bis(hydroxymethyl)benzyloxy)-2'-ethyl-2-propylbiphenyl-4-yl]pentan-3-ol | PARP2, CYP4B1, CYP8B1 | VDR 591/4885RAB9A 2546/4885KMT2A 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.